Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ELAN
BUYElanco Animal Health Incorporated · Healthcare · United States · $12.4B · Avg Vol: $116M/d
COMPANY DESCRIPTION
Elanco Animal Health Incorporated is a global leader in animal health, dedicated to developing, manufacturing, and marketing innovative products and solutions for pets and livestock across more than 90 countries. The company establishes a strong competitive moat through its diversified portfolio of essential parasiticides, vaccines, and therapeutic products, coupled with significant R&D investment and deep relationships with veterinarians and livestock producers. Elanco's focus on animal well-being and food security positions it as a resilient player in the growing animal health market.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.4B | 4.4B | 4.4B | 4.7B | 2.2% | 4.9B | 5.1B | 5.3B | 6.3% |
| EPS | -0.15 | -2.50 | 0.68 | -0.47 | — | -0.49 | — | — | — |
| Shares | 474.2M | 492.8M | 494.4M | 497.0M | +4.8% | 499.4M | — | — | — |
| Debt | 5.8B | 5.8B | 4.3B | 4.0B | -11.7% | 4.3B | — | — | — |
| Equity | 7.3B | 6.2B | 6.1B | 6.5B | -3.5% | — | — | — | — |
| Op CF | 452.0M | 271.0M | 541.0M | 560.0M | 7.4% | 577.0M | — | — | — |
| Inv CF | -179.0M | -169.0M | 1.2B | -279.0M | — | — | — | — | — |
| Fin CF | -549.0M | -83.0M | -1.5B | -275.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ELAN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ELAN | Elanco Animal Health Incorporated(you) | $12.4B | 73 | BUY |
| ZTS | Zoetis Inc. | $31.6B | 69 | BUY |
| VTRS | Viatris Inc. | $20.1B | 87 | STRONG BUY |
| NBIX | Neurocrine Biosciences, Inc. | $17.7B | 92 | STRONG BUY |
| LQDA | Liquidia Corporation | $7.7B | 55 | HOLD |
| AMRX | Amneal Pharmaceuticals, Inc. | $5.7B | 87 | STRONG BUY |
| LNTH | Lantheus Holdings, Inc. | $6.8B | 93 | STRONG BUY |
| UTHR | United Therapeutics Corporation | $26.3B | 95 | STRONG BUY |
| INDV | Indivior Pharmaceuticals, Inc. | $4.8B | 92 | STRONG BUY |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.7B | 63 | HOLD |
Peer medians: ROE -25.6% · P/E 27.7x · Gross margin 50.5%